Vogenx (NASDAQ: VOGX) has recently received a number of price target changes and ratings updates:
- 9/2/2026 – Vogenx is now covered by WBB Securities. They set a “speculative buy” rating and a $42.00 price target on the stock.
- 9/2/2026 – Vogenx is now covered by WBB Securities. They set a “speculative buy” rating and a $42.00 price target on the stock.
- 9/1/2026 – Vogenx is now covered by JonesTrading. They set a “buy” rating and a $55.00 price target on the stock.
- 8/31/2026 – Vogenx was upgraded by JonesTrading to “strong-buy”.
- 8/22/2026 – Vogenx was upgraded by Wall Street Zen to “hold”.
Vogenx Inc is a clinical-stage biopharmaceutical company. It focused on the discovery and development of novel therapeutics for the treatment of serious diseases associated with dysfunctions in human metabolism, including PBH and gastroparesis. The company’s product candidate includes mizagliflozin, is an orally administered, minimally absorbed small molecule drug candidate in development for the treatment of PBH, gastroparesis, and GIP-dependent Cushing’s Syndrome. Vogenx Inc is based in RALEIGH, NC.
Featured Stories
- Five stocks we like better than Vogenx
- 3 Under-the-Radar Defense Stocks With Record Backlogs
- This Korea ETF Has Soared, But the Rally May Not Be Over
- Why Guidewire’s Post-Earnings Plunge May Not Last
- Ride-Share Reckoning: Tesla Drives Into Uber’s Lane
Receive News & Ratings for Vogenx Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vogenx Inc and related companies with MarketBeat.com's FREE daily email newsletter.
